Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-05-31

FDA Approved: LISINOPRIL AND HYDROCHLOROTHIAZIDE — Supplemental Application (Exelan Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application to market a fixed-dose combination tablet of lisinopril and hydrochlorothiazide, manufactured by Exelan Pharmaceutic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lisinopril and Hydrochlorothiazide tablets (lisinopril and hydrochlorothiazide)

Snippet

SUPPL AP for LISINOPRIL AND HYDROCHLOROTHIAZIDE (LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS)